Galera Therapeutics, Inc. is a clinical stage biotechnology company, which engages in developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. The company is headquartered in Malvern, Pennsylvania and currently employs 3 full-time employees. The company went IPO on 2019-11-07. Its lead product candidate, avasopasem manganese (avasopasem), is a highly selective small molecule dismutase mimetic that the Company is developing for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. Its second product candidate, rucosopasem manganese (rucosopasem), is in development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The firm's new lead program is the Investigator-sponsored Phase I/II trial of a pan-NOS Inhibitor on top of standard-of-care nab-paclitaxel and alpelisib in metaplastic breast cancer.
Follow-Up Questions
Who is the CEO of Galera Therapeutics Inc?
Dr. J. Mel Sorensen is the Chairman of the Board of Galera Therapeutics Inc, joining the firm since 2012.
What is the price performance of GRTX stock?
The current price of GRTX is $0.027, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Galera Therapeutics Inc?
Galera Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Galera Therapeutics Inc market cap?
Galera Therapeutics Inc's current market cap is $2.0M
Is Galera Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Galera Therapeutics Inc, including 0 strong buy, 0 buy, 4 hold, 1 sell, and 0 strong sell
